Marpai Takes Aim at PBM Giants with 1.5 Million-Life Network Deal

TAMPA, FL – March 09, 2026 – In a strategic move poised to significantly escalate its presence in the healthcare market, technology firm Marpai, Inc. (OTCQX: MRAI) today announced a landmark marketing agreement that provides its pharmacy benefit management (PBM) division, MarpaiRx, with access to a network representing up to 1.5 million covered employees. The deal marks a potential turning point for the company, creating a powerful national distribution channel that could dramatically accelerate its growth and challenge established industry norms.

The agreement allows Marpai to introduce its suite of PBM services and broader healthcare technology to a vast new audience of large employer groups and third-party administrators. For a company whose current covered lives are in the tens of thousands, the sheer scale of the 1.5 million-life network represents an exponential leap in its addressable market and a critical catalyst for its future revenue.

"This agreement represents a major milestone for Marpai and a significant expansion of our potential growth runway," said Damien Lamendola, CEO of Marpai, Inc. in the company's official announcement. He emphasized that even "modest penetration" across this new population could generate a substantial new revenue stream and fast-track the company's growth.

A Bold Move in a Concentrated Market

Marpai's announcement lands in the middle of a highly concentrated and heavily scrutinized PBM industry. The landscape is overwhelmingly dominated by the "Big Three": CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (part of UnitedHealth Group). Together, these giants were estimated to process around 80% of all U.S. prescription claims in 2024, wielding immense power over drug pricing, pharmacy networks, and employer health plans.

This market concentration has drawn fire from regulators, lawmakers, and employers alike, who cite concerns over opaque business practices, particularly "spread pricing." In this traditional model, PBMs profit from the difference between what they charge a health plan for a drug and the lower amount they reimburse the pharmacy, a margin that is often not disclosed. This lack of transparency has fueled a growing demand for alternatives that offer clarity, accountability, and demonstrable cost savings.

The vertical integration of the largest PBMs with major insurance carriers and pharmacies has further intensified concerns about anti-competitive behavior. It is within this contentious environment that smaller, more agile players like Marpai are attempting to carve out a niche by offering a fundamentally different approach.

Championing Transparency and Technology

At the core of Marpai's strategy is a transparent, technology-enabled PBM model. Relaunched in the second half of 2025, MarpaiRx eschews the traditional opaque pricing structures in favor of a "pass-through" or transparent model. This approach typically involves passing all manufacturer rebates and pharmacy discounts directly to the employer client, with the PBM earning revenue through a clear, flat administrative fee, often on a per-member-per-month basis.

"Our MarpaiRx platform has been built specifically to scale across large populations of covered lives," stated Mimi Davis, President of MarpaiRx. "This agreement gives us the opportunity to showcase our capabilities to a very large national audience while delivering meaningful pharmacy cost savings for employers and plan members."

To deliver on this promise, the company leverages a technology platform that incorporates advanced data analytics, artificial intelligence, and real-time optimization tools. These systems are designed to analyze prescription utilization, identify cost-saving opportunities through rebate optimization and patient assistance programs, and help employers better manage the upward spiral of pharmacy costs. This tech-forward approach positions MarpaiRx as part of a new wave of PBMs seeking to disrupt the industry not just on price, but on value, data access, and member outcomes.

The 1.5 Million-Life Question

The transformational potential of the deal cannot be overstated, but it also raises critical questions about execution and scalability. The agreement provides access to a network, not a guaranteed onboarding of 1.5 million members. Marpai must now convert this access into signed contracts, a significant sales and marketing undertaking.

This initiative comes at a pivotal time for Marpai. The company experienced revenue declines in the first three quarters of 2025 and has publicly stated a goal of achieving profitability in 2026. Successfully capturing even a fraction of the new addressable market is therefore essential to reversing recent financial trends and meeting its ambitious targets.

Company leadership has expressed confidence that its infrastructure is ready for the challenge. In its announcement, Marpai asserted that its existing systems are "sufficiently robust to service the potential new members" and that its scalable platform will support increased operating leverage as new lives are onboarded. The agreement also provides a strategic opening to cross-sell Marpai's other services, including its core Third-Party Administration (TPA) and healthcare analytics capabilities, to the same client base.

As the company moves forward, the healthcare industry will be watching closely. This marketing agreement provides Marpai with an unprecedented opportunity to demonstrate its value proposition on a national scale. The focus now shifts from securing the opportunity to the formidable task of executing its strategy and converting this massive market access into the sustainable, long-term recurring revenue that will define its future in a highly competitive arena.